ข่าวประชาสัมพันธ์ Chronic Hepatitis B+Hepatitis B

Janssen to Discontinue Hepatitis C Development Program

- Viral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B Janssen Sciences Ireland UC (Janssen), today announced a strategic decision to discontinue further development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals AL-335, odalasvir and simeprevir. The ongoing phase II studies with JNJ-4178 will be completed as planned, but there will be no additional development thereafter

11 กันยายน 2560 12:44 น.

Second New England Journal of Medicine Paper Establishes PEGASYS(R) as a First-Line Therapy in Chronic Hepatitis B

PEGASYS Offers Greater Benefit Versus Current Standard of Care Results published today in the prestigious New England Journal of Medicine have led the study authors to recommend PEGASYS... มิ.ย. 48

การรักษามะเร็งตับด้วยการให้เคมีบำบัดผ่านทางหลอดเลือด — มะเร็งตับ ( Hepatocellular carcinoma ) เป็นเนื้องอกชนิดหนึ่งที่พบมากในประเทศไทย ส่วนใหญ่พบในเพศชาย... ต.ค. 61

Singapore's first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer

Lion TCR Pte. Ltd., a Singapore-based Biotech company receives approval from Health Sciences Authority (HSA), Singapore, for its Phase I/II multicentre clinical study of its product... ส.ค. 61

Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress(TM) 2016 of the European Association for the Study of the Liver (EASL)

- Includes several late breaking and oral presentations from across R&D pipeline - Highlights potential of R&D pipeline to deliver several new... มี.ค. 59

BioNet to enter Hepatitis B vaccine production

Could become the only company in the world to produce both recombinant acellular pertussis and recombinant Hepatitis B vaccines BioNet-Asia Co., Ltd., the only privately-owned biotech company in Thailand focusing on the development, manufacturing and... พ.ค. 55

World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic

- Shocking Lack of Global Statistics Prompts Creation of First Global Resource on Hepatitis: The Hepatitis Atlas The World Hepatitis Alliance, a newly formed Non-Governmental... พ.ค. 51

A Treatment-Free Life is Possible for Millions of Hepatitis B Patients, PEGASYS(R) Study Reveals

Prior Treatment with 'Maintenance Therapy' Medications No Barrier to Achieving Sustained Response with PEGASYS Hope of a treatment-free life for millions of hepatitis B patients currently having to take... มี.ค. 49

PEGASYS Doubles the Efficacy in Difficult-to-Treat Hepatitis B Virus Versus Conventional Interferon

Study results presented today at the 11th International Symposium on Viral Hepatitis and Liver Disease, Sydney Australia demonstrate that PEGASYS, a new generation hepatitis C therapy, more than... เม.ย. 46

ASIANET: Daily Summary on Monday, July 02, 2001

HEPATITIS B DEAL... CAMBRIDGE: Novirio and Sumitomo Pharmaceuticals have struck a deal for the Hepatitis B treatment, LdT, that will convey commercial rights for key Asian markets to Sumitomo, and evenly apportion development costs and sales royalties.... ก.ค. 44

ASIANET: Novirio and Sumitomo Pharmaceuticals Announce Agreement for Hepatitis B Drug

Novirio Grants Sumitomo Commercial Rights for Japan, S. Korea, Taiwan and China Novirio Pharmaceuticals Limited today announced it has entered into an agreement with Sumitomo Pharmaceuticals Co., Ltd. of Osaka,... ก.ค. 44